SEOUL PHARMA (018680) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, SEOUL PHARMA (018680) reported revenue of 52.1 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202552.1 billion KRW-1.3 billion KRW754 million KRW[source]
202453.6 billion KRW1.5 billion KRW1.7 billion KRW[source]
202352.5 billion KRW1.2 billion KRW3.5 billion KRW[source]
202250.1 billion KRW1.7 billion KRW855 million KRW[source]
202140.5 billion KRW-5.7 billion KRW-9.7 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202571.8 billion KRW30.7 billion KRW41.0 billion KRW[source]
202471.6 billion KRW31.4 billion KRW40.2 billion KRW[source]
202363.3 billion KRW24.7 billion KRW38.6 billion KRW[source]
202262.4 billion KRW27.0 billion KRW35.4 billion KRW[source]
202162.3 billion KRW43.3 billion KRW19.0 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice